CYP3A4 (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "CYP3A4" in French language version.

refsWebsite
Global rank French rank
4th place
12th place
2nd place
3rd place
6,663rd place
5,973rd place
7th place
28th place
3,306th place
2,270th place

aspetjournals.org

molpharm.aspetjournals.org

  • (en) Robertson G, Field J, Goodwin B, Bierach S, Tran M, Lehnert A, Liddle C, « Transgenic mouse models of human CYP3A4 gene regulation », Mol Pharmacol, vol. 64, no 1,‎ , p. 42–50 (PMID 12815159, DOI 10.1124/mol.64.1.42, lire en ligne)

doi.org

dx.doi.org

  • (en) Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, Kamataki T, « Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control », Eur. J. Biochem., vol. 218, no 2,‎ , p. 585–95 (PMID 8269949, DOI 10.1111/j.1432-1033.1993.tb18412.x) »
  • (en) Inoue K, Inazawa J, Nakagawa H, Shimada T, Yamazaki H, Guengerich FP, Abe T, « Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization », Jpn. J. Hum. Genet., vol. 37, no 2,‎ , p. 133–8 (PMID 1391968, DOI 10.1007/BF01899734)
  • (en) Johnson TN, Rostami-Hodjegan A, Tucker GT, « Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children », Clin Pharmacokinet, vol. 45, no 9,‎ , p. 931–56 (PMID 16928154, DOI 10.2165/00003088-200645090-00005)
  • (en) Johnson TN, Tucker GT, Rostami-Hodjegan A, « Development of CYP2D6 and CYP3A4 in the first year of life », Clin. Pharmacol. Ther., vol. 83, no 5,‎ , p. 670–1 (PMID 18043691, DOI 10.1038/sj.clpt.6100327)
  • (en) Robertson G, Field J, Goodwin B, Bierach S, Tran M, Lehnert A, Liddle C, « Transgenic mouse models of human CYP3A4 gene regulation », Mol Pharmacol, vol. 64, no 1,‎ , p. 42–50 (PMID 12815159, DOI 10.1124/mol.64.1.42, lire en ligne)
  • (en) He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF, « Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice », Chemical Research in Toxicology, vol. 11, no 4,‎ , p. 252–9 (PMID 9548795, DOI 10.1021/tx970192k)
  • (en) Bailey DG, Malcolm J, Arnold O, Spence JD, « Grapefruit juice–drug interactions », British Journal of Clinical Pharmacology, vol. 46, no 2,‎ , p. 101–10 (PMID 9723817, PMCID 1873672, DOI 10.1046/j.1365-2125.1998.00764.x)
  • (en) Garg SK, Kumar N, Bhargava VK, Prabhakar SK, « Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy », Clinical Pharmacology and Therapeutics, vol. 64, no 3,‎ , p. 286–8 (PMID 9757152, DOI 10.1016/S0009-9236(98)90177-1)
  • (en) Bailey DG, Dresser GK, « Interactions between grapefruit juice and cardiovascular drugs », American Journal of Cardiovascular Drugs, vol. 4, no 5,‎ , p. 281–97 (PMID 15449971, DOI 10.2165/00129784-200404050-00002)
  • (en) Schrøder-Aasen T, Molden G et Nilsen OG, « In vitro inhibition of CYP3A4 by the multiherbal commercial product Sambucus Force and its main constituents Echinacea purpurea and Sambucus nigra. », Phytother Res., vol. 26(11),‎ , p. 1606-13 (PMID 22319006, DOI 10.1002/ptr.4619)
  • (en) Watkins P, « Noninvasive tests of CYP3A enzymes », Pharmacogenetics, vol. 4, no 4,‎ , p. 171–84 (PMID 7987401, DOI 10.1097/00008571-199408000-00001)
  • Liao, M.; Shou, M.; Jamei, M.; Yeo, K. R.; Tucker, G. T.; Rostami-Hodjegan, A., « Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions », Current Drug Metabolism, Bentham, vol. 9, no 5,‎ , p. 384–393 (PMID 18537575, DOI 10.2174/138920008784746382, lire en ligne, consulté le )

ingentaconnect.com

  • Liao, M.; Shou, M.; Jamei, M.; Yeo, K. R.; Tucker, G. T.; Rostami-Hodjegan, A., « Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions », Current Drug Metabolism, Bentham, vol. 9, no 5,‎ , p. 384–393 (PMID 18537575, DOI 10.2174/138920008784746382, lire en ligne, consulté le )

nih.gov

ncbi.nlm.nih.gov

  • (en) Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, Kamataki T, « Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control », Eur. J. Biochem., vol. 218, no 2,‎ , p. 585–95 (PMID 8269949, DOI 10.1111/j.1432-1033.1993.tb18412.x) »
  • (en) Inoue K, Inazawa J, Nakagawa H, Shimada T, Yamazaki H, Guengerich FP, Abe T, « Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization », Jpn. J. Hum. Genet., vol. 37, no 2,‎ , p. 133–8 (PMID 1391968, DOI 10.1007/BF01899734)
  • (en) « Entrez Gene: cytochrome P450 »
  • (en) Johnson TN, Rostami-Hodjegan A, Tucker GT, « Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children », Clin Pharmacokinet, vol. 45, no 9,‎ , p. 931–56 (PMID 16928154, DOI 10.2165/00003088-200645090-00005)
  • (en) Johnson TN, Tucker GT, Rostami-Hodjegan A, « Development of CYP2D6 and CYP3A4 in the first year of life », Clin. Pharmacol. Ther., vol. 83, no 5,‎ , p. 670–1 (PMID 18043691, DOI 10.1038/sj.clpt.6100327)
  • (en) Robertson G, Field J, Goodwin B, Bierach S, Tran M, Lehnert A, Liddle C, « Transgenic mouse models of human CYP3A4 gene regulation », Mol Pharmacol, vol. 64, no 1,‎ , p. 42–50 (PMID 12815159, DOI 10.1124/mol.64.1.42, lire en ligne)
  • (en) He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF, « Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice », Chemical Research in Toxicology, vol. 11, no 4,‎ , p. 252–9 (PMID 9548795, DOI 10.1021/tx970192k)
  • (en) Bailey DG, Malcolm J, Arnold O, Spence JD, « Grapefruit juice–drug interactions », British Journal of Clinical Pharmacology, vol. 46, no 2,‎ , p. 101–10 (PMID 9723817, PMCID 1873672, DOI 10.1046/j.1365-2125.1998.00764.x)
  • (en) Garg SK, Kumar N, Bhargava VK, Prabhakar SK, « Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy », Clinical Pharmacology and Therapeutics, vol. 64, no 3,‎ , p. 286–8 (PMID 9757152, DOI 10.1016/S0009-9236(98)90177-1)
  • (en) Bailey DG, Dresser GK, « Interactions between grapefruit juice and cardiovascular drugs », American Journal of Cardiovascular Drugs, vol. 4, no 5,‎ , p. 281–97 (PMID 15449971, DOI 10.2165/00129784-200404050-00002)
  • (en) Bressler R, « Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs », Geriatrics, vol. 61, no 11,‎ , p. 12–8 (PMID 17112309)
  • (en) Schrøder-Aasen T, Molden G et Nilsen OG, « In vitro inhibition of CYP3A4 by the multiherbal commercial product Sambucus Force and its main constituents Echinacea purpurea and Sambucus nigra. », Phytother Res., vol. 26(11),‎ , p. 1606-13 (PMID 22319006, DOI 10.1002/ptr.4619)
  • (en) Watkins P, « Noninvasive tests of CYP3A enzymes », Pharmacogenetics, vol. 4, no 4,‎ , p. 171–84 (PMID 7987401, DOI 10.1097/00008571-199408000-00001)
  • Liao, M.; Shou, M.; Jamei, M.; Yeo, K. R.; Tucker, G. T.; Rostami-Hodjegan, A., « Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions », Current Drug Metabolism, Bentham, vol. 9, no 5,‎ , p. 384–393 (PMID 18537575, DOI 10.2174/138920008784746382, lire en ligne, consulté le )

nytimes.com

  • Bakalar, Nicholas. Experts Reveal the Secret Powers of Grapefruit Juice. New York Times. Published: March 21, 2006. Article